Pulmonx LUNG
- Market cap
- $110.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $87.4M
- −3% on a year ago
- Net margin
- −55.0%
- Free cash flow yield
- −27.7%
Pulmonx trades at 1.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $87.4M over the last twelve months, down 3% on a year earlier with a −55% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $17.7M+31% | $19.3M+25% | $18.9M+30% | $20.8M+21% | $20.4M+15% | $23.8M+23% | $22.5M+20% | $23.9M+15% | $21.5M+6% | $22.6M−5% | $20.6M−9% | $22.8M−5% | |
| Cost of revenue | $4.6M+39% | $4.9M+15% | $4.8M+21% | $5.5M+23% | $5.4M+16% | $6.2M+27% | $6.2M+30% | $6.7M+22% | $5.5M+2% | $5.1M−18% | $4.5M−27% | $5M−25% |
| Gross profit | $13M+28% | $14.4M+29% | $14.1M+33% | $15.3M+20% | $15M+15% | $17.6M+22% | $16.3M+16% | $17.2M+12% | $16.1M+7% | $17.5M−0% | $16M−2% | $17.7M+3% |
| R&D | $4.2M−3% | $3.9M−0% | $4.2M−1% | $5.6M−2% | $3.7M−11% | $4M+3% | $4.8M+13% | $5.3M−6% | $4.8M+29% | $4.6M+15% | $4.9M+3% | $5M−5% |
| SG&A | $24M+22% | $24.4M+12% | $24.4M+7% | $25.3M+8% | $25.4M+6% | $27M+11% | $26.1M+7% | $26.7M+6% | $25.6M+1% | $22.9M−15% | $24.1M−8% | $21.8M−19% |
| −$15.2M+9% | −$13.9M−5% | −$14.5M−11% | −$15.6M−5% | −$14.1M−7% | −$13.4M−4% | −$14.6M+0% | −$14.8M−5% | −$14.4M+2% | −$9.9M−26% | −$13M−11% | −$9.1M−39% | |
| Interest expense | $893K+212% | $905K+152% | $883K+55% | $891K+3% | $891K−0% | $842K−7% | $781K−12% | $799K−10% | $805K−10% | $770K−9% | $976K+25% | $1.2M+52% |
| Pre-tax income | −$14.8M+5% | −$13.6M−3% | −$13.6M−14% | −$15.2M−5% | −$14M−6% | −$13.1M−4% | −$14.3M+6% | −$15M−2% | −$13.8M−1% | −$10.2M−22% | −$13.5M−6% | −$9.9M−34% |
| $59K | $248K+1% | $186K+50% | $84K−40% | $192K+225% | $38K−85% | $135K−27% | $177K+111% | $128K−33% | $186K+390% | $149K+10% | $133K−25% | |
| Net income | −$14.9M+5% | −$13.9M−3% | −$13.7M−13% | −$15.3M−5% | −$14.1M−5% | −$13.2M−5% | −$14.4M+5% | −$15.2M−1% | −$14M−1% | −$10.4M−21% | −$13.7M−6% | −$10.1M−34% |
| −$0.39+3% | −$0.36−5% | −$0.36−14% | −$0.39−9% | −$0.36−8% | −$0.33−8% | −$0.36+0% | −$0.38−3% | −$0.34−6% | −$0.25−24% | −$0.33−8% | −$0.24−37% | |
| 38.1M+3% | 38.4M+3% | 38.6M+3% | 38.9M+3% | 39.3M+3% | 39.6M+3% | 40M+3% | 40.4M+4% | 40.9M+4% | 41.4M+5% | 41.9M+5% | 42.5M+5% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Pulmonx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LUNGPulmonx | $110.8M | n/m | n/a | 1.3× | −3% | −55.0% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| NEPHNephros | $35.2M | 20.3× | 28.3× | 1.7× | +24% | 8.4% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| Peer median | $250.1M | 19.0× | 18.7× | 1.6× | +6% | 7.7% |
More on Pulmonx
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .